$CMPS News
Last published 21h ago
- 21h agoCMPSCompass Pathways to Participate in Jefferies Global Healthcare Conference on November 18th and 19thBusiness WireLONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the Jefferies Global Healthcare Conference on November 18 and 19, 2026 and will participate in a fireside chat on November 18 at 9:00am GMT and a p ...
- 2d agoCMPSCompass Pathways Completes COMP360 Psilocybin New Drug Application to U.S. FDA for Treatment-Resistant DepressionBusiness WireLONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the Company completed its submission of a New Drug Application (NDA) to the U.S. FDA for COMP360 psilocybin, its investigational synthetic, proprietary formulation of psilocyb ...
- 1w agoCMPSCOMPASS Pathways plc - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2w agoCMPSCompass Pathways to Highlight Scientific Research and TRD Disease State Education Efforts at the 2026 Neuroscience Education Institute Fall CongressBusiness WireDisease education booth underscores continued commitment to advancing understanding of treatment-resistant depression (TRD) among U.S. healthcare professionals (HCPs) Encore poster presentations highlight key
- 2w agoCMPSCompass Pathways to Announce Third Quarter 2026 Financial Results on November 3, 2026Business WireCompass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that it will release financial results for the third
- 4w agoCMPSCompass Pathways Joins Forces with Leading Mental Health Organizations to Mark First-Ever U.S. Treatment-Resistant Depression (TRD) Awareness DayBusiness WireFirst-ever Treatment-Resistant Depression (TRD) Awareness Day establishes dedicated moment to recognize and raise awareness of the condition’s profound impact on patients and their loved ones Survey data in a new
- 1mo agoCMPSCompass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireCompass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass
- 1mo agoCMPSCompass Pathways Appoints Kelley Boucher as Chief People OfficerBusiness WireCompass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced the appointment of Kelley Boucher as Chief People Officer,
- 1mo agoCMPSCompass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026Business WireCompass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the TD Cowen 6th Annual Novel
- 1mo agoCMPSCompass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 2026Business WireNew U.S. healthcare provider (HCP) disease education initiative, Change the Tune in TRD explores the neurobiology and care pathways to support greater recognition and understanding of treatment-resistant depression
- 2mo agoCMPSStrata Mental Health Solutions Awarded U.S. Healthcare Provider Training Grant from Compass Pathways to Develop Provider Training for COMP360Business WireStrata’s implementation platform includes provider training, certification, site readiness, and ongoing clinical support; its founders worked with Compass on the COMP360 training program for clinicians, who supported
- 2mo agoCMPSCompass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider TrainingBusiness WireFive organizations awarded grants, above the planned three, as a result of a competitive selection process with highly qualified applicants Training guidance is designed to prepare healthcare providers to deliver
- 2mo agoCMPSCompass Pathways to Participate in Investor Conferences the Week of September 14thBusiness WireCompass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will participate in the following investor
- 2mo agoCMPSCompass Pathways’ New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 YearBusiness WireNotable additional benefit observed with an added reduction in MADRS1 score leading to an average 13-point reduction from baseline at Week 52 with durability extended out to 1 year for participants who were randomized
- 2mo agoCMPSCompass Pathways to Debut U.S. HCP Education Campaign and Present New HEOR Data at Psych Congress 2026Business WireCompass will debut Change the Tune in TRD, a new U.S. healthcare provider (HCP) education campaign for treatment-resistant depression (TRD) at Booth #901 Seven poster presentations include new health economics and
- 2mo agoCMPSCompass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireCompass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass
- 2mo agoCMPSCompass Pathways Recognized as a 2026 Fierce 50 Breakthrough HonoreeBusiness WireCompass Pathways, a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, has been named a 2026 Fierce 50 Breakthrough honoree by Fierce Pharma, Fierce Biotech and
- 2mo agoCMPSCompass Pathways to Participate in 2026 Cantor Global Healthcare Conference on September 9, 2026Business WireCompass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the 2026 Cantor Global
- 3mo agoCMPSCompass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026Business WireCompass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the Canaccord Genuity's
- 3mo agoCMPSCompass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of PsilocybinBusiness WireCompass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today it is working with the U.S. Department of Verterans
- 3mo agoCMPSCompass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireCompass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass
- 3mo agoHELPDFTXCMPSJNJ+1A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 ReadoutGlobeNewswireNEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary - In biotech, the gap between a promising drug and a commercial success is often bridged by a single thing: the operator who has done it
- 3mo agoCMPSCompass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business HighlightsBusiness WireData from two positive Phase 3 trials demonstrated rapid onset of effect and durable benefit through at least 6 months, further validating COMP360’s potential to establish a new standard of care in TRD COMP360 has
- 3mo agoCMPSCompass Pathways to Announce Second Quarter and First Half 2026 Financial Results on August 5, 2026Business WireCompass Management will host a conference call at 8:00 am ET (1:00 pm UK) Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health
- 3mo agoHELPCMPSGHRSDFTX+1A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps WideningPR NewswireUSA News Group - News Commentary - Depression remains one of the most stubborn problems in modern medicine, and the numbers behind it are staggering. ...
- 3mo agoHELPLLYATAICMPS+1Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation AcceleratesPR NewswireMarket News UpdatesNews Commentary - Globally, Major Depressive Disorder (MDD) is a prevalent mental health condition that has seen an improvement in ...
- 3mo agoLLYDFTXCMPSHELP+4The market for psychedelic drugs to treat mental health conditions gets a big buy signalCNBCEli Lilly's acquisition of psychedelic drug maker AtaiBeckley extends Big Pharma's embrace of a stigmatized class of medications for treating mental health.
- 3mo agoHELPLLYATAICMPS+2Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real TimePR NewswireFor half a century, psychedelic medicine was the field serious money would not touch. That ended this morning. Eli Lilly and Company (NYSE: LLY)...
- 3mo agoCMPSCompass Pathways Announces Publication of Post-Hoc Analysis Demonstrating Distinction of COMP360 Trial Monitoring & Support from PsychotherapyBusiness WirePost-hoc analysis of support methods used in an open-label Phase 2 COMP360 study showed monitoring and support provided during treatment administration sessions were minimal, non-directive and distinct from
- 4mo agoCMPSCompass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable ProfileBusiness WireNew 6-month data supports COMP360’s potential to establish a new standard of care in TRD Data from positive COMP006 Phase 3 trial demonstrates durable benefit through at least 6 months further validating COMP360’s
- 4mo agoCMPSCompass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireCompass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass
- 4mo agoHELPDFTXCMPSGHRS+1Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge OpportunityGlobeNewswireNEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The way Major Depressive Disorder (MDD) is treated is changing faster than it has in years. For decades, most patients relied on
- 4mo agoKLRACMPSSPROKailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs OfficerGlobeNewswireWALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Kathleen
- 4mo agoHELPCMPSDFTXGHRSA Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This YearPR NewswireUSA News Group News Commentary, In drug development, enrollment is the quiet variable that decides whether a promising therapy ever reaches a data...
- 5mo agoCMPSCompass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireCompass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass
- 5mo agoCMPSSPROCompass Pathways Elects Kathleen Tregoning to Board of DirectorsBusiness WireCompass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the election of Kathleen Tregoning to its Board of
- 5mo agoCMPSCompass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 2026Business WireCompass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the Jefferies Global
- 6mo agoCMPSCompass Pathways to Participate in RBC Capital Markets Global Healthcare Conference on May 19-20, 2026Business WireCompass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the RBC Capital Markets
- 6mo agoCMPSCompass Pathways Announces First Quarter 2026 Financial Results and Business HighlightsBusiness WireFDA granted Compass NDA rolling submission and review request, based on strength of Phase 3 data CNPV awarded for COMP360 in TRD, further accelerating momentum 26-week (Part B) data from COMP006, expected in
- 6mo agoCMPSCompass Pathways to Announce First Quarter 2026 Financial Results on May 13, 2026Business WireCompass management will host a conference call at 8:00 am ET (1:00 pm UK) Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental
- 6mo agoCMPSCompass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireCompass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass
- 6mo agoCMPSCompass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority VoucherBusiness WireCompass is the most advanced company in classic psychedelics and has generated positive data from two ongoing large, well controlled Phase 3 clinical trials, designed to uphold the highest regulatory standards FDA
- 6mo agoAAPL.IXIC.SPX.RUT+6Apple's next CEO, Warsh's confirmation hearing, the psychedelic stock surge and more in Morning SquawkCNBCHere are five key things investors need to know to start the trading day.
- 6mo agoCMPSCompass Pathways Collaborates with Osmind to Advance Independent Clinic Readiness for Psychedelic TreatmentsBusiness WireCompass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it has entered into a collaboration with Osmind, the platform powering a
- 6mo agoATAICMPSHELPDFTXHow Trump's psychedelics executive order could unlock stalled cannabis reformCNBCThe White House psychedelics executive order accelerates research, clinical trials and "Right to Try" access for drugs like psilocybin, MDMA and ibogaine.
- 6mo agoCMPSCompass Pathways to Participate in Needham Virtual Psychedelics Forum on April 27, 2026Business WireCompass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that CEO Kabir Nath will participate in a panel
- 6mo agoCMPSCompass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic TreatmentsBusiness WireCompass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical treatments for serious
- 7mo agoCMPSCompass Pathways Announces U.S Grant Program for the Creation of Post-Approval COMP360 Provider TrainingBusiness WireCompass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today an invitation for U.S. based organizations to apply for
- 7mo agoCMPSCompass Pathways to Attend Needham Virtual Healthcare Conference on April 14, 2026Business WireCompass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the Needham Virtual
- 7mo agoCMPSCompass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireCompass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass